NEW YORK – Alameda, California-based Exelixis on Monday announced that it has initiated a Phase I clinical trial evaluating its CDK7 inhibitor, XL102, as a treatment for patients with advanced solid tumors.
NEW YORK – Alameda, California-based Exelixis on Monday announced that it has initiated a Phase I clinical trial evaluating its CDK7 inhibitor, XL102, as a treatment for patients with advanced solid tumors.
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.